Market closed
Acasti Pharma, Inc./$GRCE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Acasti Pharma, Inc.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Ticker
$GRCE
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
32
Website
GRCE Metrics
BasicAdvanced
$30M
-
-$1.16
1.20
-
Price and volume
Market cap
$30M
Beta
1.2
52-week high
$4.69
52-week low
$1.75
Average daily volume
29K
Financial strength
Current ratio
6.057
Quick ratio
5.762
Management effectiveness
Return on assets (TTM)
-15.16%
Return on equity (TTM)
-22.89%
Valuation
Price to book
0.42
Price to tangible book (TTM)
7.62
Price to free cash flow (TTM)
-1.767
Growth
Earnings per share change (TTM)
-74.43%
3-year earnings per share growth (CAGR)
-24.95%
GRCE News
AllArticlesVideos
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
GlobeNewsWire·1 week ago
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewsWire·1 month ago
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Acasti Pharma, Inc. stock?
Acasti Pharma, Inc. (GRCE) has a market cap of $30M as of April 17, 2025.
What is the P/E ratio for Acasti Pharma, Inc. stock?
The price to earnings (P/E) ratio for Acasti Pharma, Inc. (GRCE) stock is 0 as of April 17, 2025.
Does Acasti Pharma, Inc. stock pay dividends?
No, Acasti Pharma, Inc. (GRCE) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Acasti Pharma, Inc. dividend payment date?
Acasti Pharma, Inc. (GRCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Acasti Pharma, Inc.?
Acasti Pharma, Inc. (GRCE) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.